4.50

3.64% -0.17

Cingulate Inc (CING)

Overview News Price History Financials Discussions Forecast

Cingulate Inc stock is traded at $4.50, with a volume of 49,175. It is down -3.64% in the last 24 hours and down -4.26% over the past month. Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.

Previous Close:

$4.67

Open:

$4.8

24h Volume:

49,175

Relative Volume:

0.29

Market Cap:

$15.00M

Revenue:

Net Income/Loss:

$-21.21M

P/E Ratio:

-0.138

EPS:

-32.6

Net Cash Flow:

$-16.86M

1W Performance:

-1.10%

1M Performance:

-4.26%

6M Performance:

+38.33%

1Y Performance:

-65.60%

1-Day Range:

$4.43

$4.89

1-Week Range:

$4.35

$5.03

52-Week Range:

$1.8001

$20.83

Cingulate Inc Stock (CING) Company Profile

Name

Cingulate Inc

Sector

Healthcare (1187)

Industry

Biotechnology (679)

Phone

(913) 942-2300

Address

1901 W. 47TH PLACE, KANSAS CITY

Employee

Twitter

Next Earnings Date

Latest SEC Filings

CING's Discussions on Twitter

Compare CING with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CING Cingulate Inc	4.48	15.00M	0	-21.21M	-16.86M	-32.60
VRTX Vertex Pharmaceuticals Inc	472.57	123.91B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	715.64	78.94B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	653.31	39.98B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	275.20	35.89B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	118.67	28.75B	3.30B	-501.07M	1.03B	-2.1146

Cingulate Inc Stock (CING) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-10-25	Initiated	ROTH MKM	Buy
Dec-22-23	Downgrade	Laidlaw	Buy → Hold

Cingulate Inc Stock (CING) Latest News

Feb 04, 2025

Cingulate stock price target raised to $20 at H.C. Wainwright - MSN

Feb 04, 2025

Cingulate CEO cleared of charges, retains board confidence - Investing.com India

Feb 04, 2025

Cingulate CEO cleared of charges, retains board confidence By Investing.com - Investing.com Australia

Feb 04, 2025

Feb 03, 2025

Cingulate stock price target raised to $20 at H.C. Wainwright By Investing.com - Investing.com Nigeria

Jan 30, 2025

Meta Platforms To Rally Over 29%? Here Are 10 Top Analyst Forecasts For Thursday - Benzinga

Jan 30, 2025

Jan 29, 2025

Public company CEO concludes case alleging aggravated domestic battery - The Business Journals

Jan 29, 2025

Jan 24, 2025

Cingulate Inc. adjusts executive compensation By Investing.com - Investing.com Australia

Jan 24, 2025

Jan 15, 2025

Jane Street Group LLC Invests $106,000 in Cingulate Inc. (NASDAQ:CING) - Defense World

Jan 15, 2025

Jan 12, 2025

Cingulate stock rated Buy by Roth/MKM, anticipates $1.6B sales potential - Investing.com Canada

Jan 12, 2025

Cingulate (NASDAQ:CING) Coverage Initiated at Roth Mkm - Defense World

Jan 12, 2025

Roth Capital Upgrades Cingulate (NASDAQ:CING) to “Strong-Buy” - Defense World

Jan 12, 2025

Jan 10, 2025

Roth MKM Initiates Coverage of Cingulate (CING) with Buy Recommendation - MSN

Jan 10, 2025

Jan 07, 2025

CINGWCingulate Inc. Warrants Latest Stock News & Market Updates - StockTitan

Jan 07, 2025

Cingulate Inc Completes Key FDA Study for ADHD Drug - TipRanks

Jan 07, 2025

Final Study Completed for Cingulate’s Lead Asset CTx-1301 - GlobeNewswire

Jan 07, 2025

Cingulate Completes Final FDA Study for Once-Daily ADHD Drug CTx-1301 with Zero Safety Issues - StockTitan

Jan 07, 2025

Dec 26, 2024

Cingulate Inc. Enters into Note Purchase Agreement with Streeterville Capital, LLC - Defense World

Dec 26, 2024

Dec 24, 2024

Cingulate secures capital ahead of 2025 plans to submit drug for FDA approval - The Business Journals

Dec 24, 2024

Cingulate Inc Secures $5M Financing for Strategic Growth - Yahoo Finance

Dec 24, 2024

Dec 23, 2024

Cingulate Inc. announced that it has received $5 million in funding - Marketscreener.com

Dec 23, 2024

Cingulate Completes Financing Transaction for Net Proceeds of $5,000,000 - GlobeNewswire

Dec 23, 2024

Cingulate Secures $5M Financing Deal to Advance CTx-1301 Drug Development Through 2025 - StockTitan

Dec 23, 2024

Nov 23, 2024

Cingulate (NASDAQ:CING) Upgraded at Maxim Group - Defense World

Nov 23, 2024

Nov 11, 2024

U.S. Stock market top gainers: Binah Capital Group gains +107.02%, Aligos Therapeutics surges by 42.84% in mid day trading - Business Upturn

Nov 11, 2024

Cingulate Inc. Announces Third Quarter Financial Results and Clinical Update - Defense World

Nov 11, 2024

Nov 07, 2024